Target Audience
BCPPs who value and learn through case-based literature offering therapeutic advice on both evidence and longstanding clinical experience are the target audience for this product. New and experienced BCPPs desiring insights into the strategies of clinical decision-making used by expert clinicians will find value in this product as the articles focus on disease states, their pharmacotherapy, and the synthesis of solutions to challenges that require judgement(s) founded on evidence but modified or tempered by extensive clinical experience and practicalities of "real world" necessities.
Course Requirements
To satisfactorily complete the recertification programming and receive BCPP Recertification and ACPE credit, candidates must meet the following requirements:
- Register for this course.
- Complete the pre-test before starting the activity.
- Review the full content of the activity and reflect upon its teachings.
- Abide by a confidentiality and honesty statement requiring individual completion of the course.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete an activity evaluation form.
- Wait for an official review of exam questions within 4 weeks following the closing date.
- Receive a passing grade (75%).
- Partial credit is not provided; your exam score must meet or exceed the cut-off score in order to receive the ACPE and BCP Recertification credit.
- Learners who do not achieve a passing score on a post-activity assessment may appeal assessment questions and/or take a remediation assessment. View AAPP's Post-Activity Assessment Appeal and Remediation Policy.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
View biographical information
Dana Chiulli, PharmD, BCPP
Clinical Pharmacist Practitioner - Mental Health
VISN 06 Mental Health Clinical Resource Hub
Flower Mound, TX
Courtney Iuppa, PharmD, BCPP
Clinical Pharmacy Manager & Residency Program Director
Center for Behavioral Medicine
Kansas City, MO
Kayla Johnson, PharmD, BCPS, BCPP
Clinical Pharmacist Specialist
Vanderbilt University Medical Center
Thompsons Station, TN
Megan O’Connell, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry and Neurology
Michigan Medicine
Ann Arbor, MI
Amy VandenBerg, PharmD, BCPP
Clinical Associate Professor and Clinical Specialist - Psychiatry & Neurology
University of Michigan College of Pharmacy and Michigan Medicine
Ann Arbor, MI
Learning Objectives
- Apply risk mitigation strategies to patients with suicidality who are taking opioids for complex pain syndromes.
- Determine an appropriate opioid taper for a patient with chronic pain and suicidality based on patient-specific factors.
- Recommend a treatment plan, including modifiable risk factors, for a patient experiencing suicidality related to chronic pain.
Involuntary Medication Treatment of Schizophrenia in the Inpatient Setting
- Interpret clinical features and treatment issues as applicable to patients receiving involuntary treatment of schizophrenia.
- Evaluate risks and benefits of available treatment options for schizophrenia and the evidence supporting them.
- Apply evidence and/or expert opinion to optimize involuntary treatment for a patient with schizophrenia.
Clinical experience and treatment considerations with Vesicular Monoamine Transporter 2 Inhibitors
- Educate patients on the potential risks and benefits of VMAT2i therapy.
- Design a therapeutic treatment plan for a patient initiating VMAT2i treatment.
- Assess the evidence for use of VMAT2i outside of Food and Drug Administration approved labeling.
Clinical Pearls for the Management of Duloxetine in Patients with Medical Comorbidities
- Interpret pharmacokinetic information related to duloxetine treatment.
- Evaluate risks and benefits of available treatment options for a patient with changes in nutrition status.
- Apply evidence and/or expert opinion to optimize duloxetine treatment for a patient with renal or hepatic impairment.
- Choose therapeutic management options for complex clinical situations involving duloxetine and interacting medications.
Continuing Education Credit and Disclosures
Activity Dates: 12/12/2024 - 06/17/2025
ACPE Contact Hours: 5
ACPE Numbers: 0284-0000-24-042-H01-P (Application), 0284-0000-24-043-H01-P (Application), 0284-0000-24-044-H01-P (Application), 0284-0000-24-045-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Psychopharmacology Pearls product is an application-based program approved for 5 ACPE contact hours. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2024 Psychopharmacology Pearls Editorial Board
No Relevant Financial Relationships to Disclose
All relevant relationships have been mitigated.
View independent reviewer disclosures
The articles in this learning activity were developed by the authors in conjunction with the planning committee. Each article subsequently was peer-reviewed and copyedited by the Mental Health Clinician (MHC) prior to publication. As a scholarly journal, the MHC utilizes external double-blind peer review such that reviewer details are not presented here. MHC Editorial Board policies are online.
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.